News | Artificial Intelligence | October 24, 2019

Medical AI software company and U.S. cancer center operator partner to further advance early detection and characterization of various cancers with artificial intelligence

Enlitic Announces Strategic Partnership With Select Healthcare Solutions

October 24, 2019 — Artificial intelligence (AI) software developer Enlitic Inc. announced it has signed a strategic partnership with Select HealthCare Solutions, a developer, owner and operator of cancer centers across the U.S. As part of the agreement, Enlitic will receive access to Select Healthcare’s high-quality, anonymized patient data –– data that will further tune Enlitic’s predictive models for early cancer detection. In turn, Select HealthCare will receive access to Enlitic’s AI software technology and will directly contribute to the development of future Enlitic products in radiology, oncology and pathology.

Enlitic’s deep learning models have demonstrated potential for the early detection of malignancies. In an independent validation study from 2017, Enlitic's algorithm was found to detect lung nodules with 91.1 percent sensitivity at time of biopsy, operating on par with state-of-the-art computer-aided detection (CAD), but with much higher specificity. Furthermore, the algorithm was shown to detect malignancies 6 and 12 months before biopsy, and reliably caught cancerous nodules 17.5 months earlier than when a biopsy was ordered.

Enlitic’s partnership with Select HealthCare adds to Enlitic’s global partnership roster of healthcare and technology companies, including Capitol Health, a leading Australian healthcare provider; Marubeni Corp., a Japan-based global conglomerate; and Konica Minolta, a multinational technology company also based in Japan.

“Enlitic’s diagnostic AI software is crucial to improving patient care in the future and we are excited to join the company’s list of world-class partners by providing comprehensive multimodal data that will help revolutionize how cancer is detected and treated,” said Matthew Cutler, president and CEO of Select HealthCare Solutions. “We believe that our clinical experience in treating complex cancers, combined with Enlitic’s best-in-class technologies and experience in early disease detection, will ultimately help save millions of lives.”

For more information: www.enlitic.com


Related Content

News | Stroke

March 11, 2026 — Brainomix, a provider of AI-powered imaging tools for stroke and lung fibrosis, has announced the ...

Time March 11, 2026
arrow
News | HIMSS

March 9, 2026 — Fujifilm Healthcare Americas Corp. is showcasing how its latest AI-powered enterprise imaging solutions ...

Time March 10, 2026
arrow
News | HIMSS

March 5, 2026 — At the Health Information and Management Systems Society (HIMSS) Conference & Exhibition 2026 in Las ...

Time March 06, 2026
arrow
News | Radiation Oncology

March 4, 2026 — Lunit has announced that 21 studies featuring its AI solutions will be presented at the European ...

Time March 05, 2026
arrow
News | Ultrasound Women's Health

March 2, 2026 — Ultrasound AI, a provider of artificial intelligence applications for medical imaging, has received FDA ...

Time March 03, 2026
arrow
News | FDA

Feb. 26, 2026 — The U.S. Food and Drug Administration (FDA) has given 510(k) class II clearance of qXR-Detect, the ...

Time February 26, 2026
arrow
News | Ultrasound Imaging

Feb. 25, 2026 — GE HealthCare is introducing the next generation of LOGIQ general imaging ultrasound systems – an ...

Time February 25, 2026
arrow
News | Women's Health

Feb.23, 2026 — The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in ...

Time February 23, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 19, 2026 — GE HealthCare recently announced 510(k) clearance of three new magnetic resonance (MR) innovations with ...

Time February 20, 2026
arrow
News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
Subscribe Now